Endovalve makes progress with percutaneous valve replacement:
This article was originally published in Clinica
Executive Summary
Endovalve has met some early milestones regarding the development of its percutaneous valve replacement system for treating mitral regurgitation. It has developed a to-scale functional model of the valve and anchor design, and has successfully demonstrated such feasibility criteria as foldability and deployment of the nitinol and stainless steel device, said the Princeton, New Jersey company. Bench testing on ex vivo sheep hearts has shown that when the valve device drops from the left atrium into the native mitral valve, it pushes away the native leaflets and is seated in place. The product's valve claws have also been shown to be able to "anchor" themselves onto the native annulus. Endovalve is now working on refining and optimising the valve's functionality, with a view to implanting the device in a live animal model.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.